MATERIAL CONTRACTS 22 As of the date of this Registration Document, we are a party to the • Master agreement relating to the Sight Again Program between following material contracts: Bpifrance Financement, Pixium Vision and the Company dated December 16, 2014. In December 2014, we entered into a master agreement relating 22.1 to the Program with Bpifrance Financement, Pixium Vision COLLABORATION, PARTNERSHIP AND RELATED and FVE setting forth the characteristics of the Program, to AGREEMENTS fix the amount and conditions for awarding funding granted Agreements Relating to GS010 by Bpifrance Financement as wel l as to clarify the principles • Partnership agreement relating to the research, development and arrangements for monitoring the implementation of the and commercialization of GS010 between Genethon and the Program by Bpifrance Financement. Pursuant to an amendment Company dated February 1, 2013, as amended from time to dated November 26, 2015, the product candidate known as time. GS020 has been replaced by the product candidate GS030 for the purpose of the agreement. For more details, see Section 11.4, In February 2013, we entered into a partnership agreement “Col laboration, Partnership and Related Agreements” of this with Genethon to research, develop and commercialize selected Registration Document. research and development projects for gene therapy products within specific ocular indications using technology licensed by • Financial aid agreement related to the Sight Again Program the Company under a license agreement with Inserm Transfert between Bpifrance Financement and the Company dated dated October 12, 2012. For more details, see Section 11.4, December 16, 2014. “Col laboration, Partnership and Related Agreements” of this In December 2014, we entered into a financial aid agreement Registration Document. relating to the Program with Bpifrance Financement setting forth Agreements Relating to GS030 the amounts and conditions upon which Bpifrance Financement shall grant financial aid to the Program. Pursuant to an amendment • Research collaboration agreement relating to the development dated November 26, 2015, the product candidate known as and testing of optogenetic tools between the Friedrich GS020 has been replaced by the product candidate GS030 for Miescher Institute and the Company dated March 1, 2014. the purpose of the agreement. For more details, see Section 11.4, On March 1, 2014, we entered into a research col laboration “Col laboration, Partnership and Related Agreements” of this agreement with the FMI , under which the parties agreed to Registration Document. col laborate in research comprising the design, planning and Agreements Relating to GS010 and GS030 carrying out of experiments on different animal models with the aim of testing new therapeutic approaches, including the • Cooperation agreement relating to research and development development and testing of optogenetic tools. Pursuant to an in ophtalmic diseases between UPMC, INSERM, CNRS, Institut amendment signed in March 2017, the agreement will remain in de la Vision and the Company dated December 19, 2013. force until May 31, 2018, subject to prior termination. For more In December 2013, we entered into a framework agreement with details, see Section 11.4, “Collaboration, Partnership and Related UPMC, Institut National de la Santé etde la Recherche Médicale, Agreements” of this Registration Document. Centre National de la Recherche Scientifique and Centre de Recherche Sight Again Program Institut de laVision under which the parties agree to create a partnership in the field of research and development in ophthalmic • Consortium agreement relating to the research and diseases. This framework agreement has been amended in development of complimentary therapeutic remedies between March 2014, December 2014, June 2015 and January 2016. Pixium Vision S.A., or Pixium Vision, Fondation Voir et Entendre As part of the framework agreement, we also entered into three and the Company dated July 11, 2014. specific research agreements between UPMC, INSERM, CNRS In July 2014, we entered into a consortium agreement with and the Company in October 2014, November 2014, June 2015 Pixium Vision and FVE. For more details, see Section 11.4, and December 2016. Formore details, see Section 11.4, “Col laboration, Partnership and Related Agreements” of this “Col laboration, Partnership and Related Agreements” of this Registration Document. Registration Document. 232– GENSIGHT BIOLOGICS – 2017 Registration Document